Daiichi Sankyo Company Limited (DSKYF.PK) News Headlines

▮ More

Date

Headline

8/15/2022 2:23:00 AM AstraZeneca: DESTINY-Breast02 Results Confirm Efficacy Seen In Previous Trials Of ENHERTU

8/11/2022 11:52:00 PM AZN : Enhertu Approved In U.S. As First HER2 Directed Therapy For HER2 Mutant Metastatic NSCLC

8/8/2022 8:05:39 AM Daiichi Sankyo : Phase 3 Trial Of Patritumab Deruxtecan Initiated In Patients With EGFR-Mutated Metastatic NSCLC

8/5/2022 10:42:33 PM AstraZeneca : FDA Approves Enhertu For HER2-low Metastatic Breast Cancer

7/19/2022 2:42:22 AM AstraZeneca, Daiichi Sankyo Announce Approval Of Enhertu In The EU

6/27/2022 2:29:41 AM AstraZeneca : Enhertu Recommended For Approval In EU By CHMP For Metastatic Breast Cancer

6/27/2022 2:28:06 AM AstraZeneca Says Enhertu Recommended For EU Approval For Breast Cancer

6/5/2022 10:00:23 PM AZN : Enhertu Reduces Risk Of Disease Progression Or Death By 50% In Metastatic Breast Cancer

2/21/2022 2:51:47 AM AZN : ENHERTU Improves PFS & Overall Survival In Phase 3 Trial On HER2 Low Metastatic Breast Cancer

12/20/2021 1:20:15 AM Vifor Pharma Settles Patent Litigations Regarding Injectafer - Quick Facts

9/20/2021 2:29:16 AM AstraZeneca: Enhertu Triples Progression-free Survival In Phase III DESTINY-Breast03 Trial

8/9/2021 2:46:10 AM AstraZeneca : Enhertu Improves PFS In Phase 3 Trial On Metastatic Breast Cancer

4/27/2021 5:52:09 AM Daiichi Sankyo FY20 Profit Down; Sees Higher Operating Profit, Revenues In FY21

4/27/2021 5:09:16 AM Daiichi Sankyo FY EPS 39.11 Yen Vs 66.27 Yen Last Year

1/20/2021 2:30:49 AM AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Breast Cancer

1/18/2021 3:00:48 AM AstraZeneca, Daiichi Sankyo: Enhertu Gets US Approval For HER2-positive Advanced Gastric Cancer

1/18/2021 2:03:37 AM AstraZeneca And Daiichi Sankyo Announce Enhertu Approved In The US For Gastric Cancer

Older Articles